Bayer looks to leverage AI across the pharma value chain

| March 21, 2018

article image
Bayer has already shown more than a passing interest in artificial intelligence through its digital accelerator programme Grants4Apps, but the company’s use of the technology looks to be more wide-ranging and deep-seated than that. Talking to journalists after the company’s Financial News Conference late last month in Leverkusen, Germany, the president of Bayer Pharma Dieter Weinand spoke of his hopes for AI. The company is, he said, “all over this”, having already collaborated with the likes of Verily, the life sciences unit at Google parent company Alphabet, and IBM’s Watson and Deep Blue. “We’re looking into all these areas across the entire value chain, from R&D all the way to commercial.” Spearheading some of this work is Bayer’s LifeScience iHub, a Silicon Valley-based innovation centre set up in 2015 to focus on developing new digital solutions.

Spotlight

STADA

STADA Arzneimittel AG as parent company of the STADA Group based in Bad Vilbel, Germany, is a publicly-listed, internationally oriented company.

OTHER ARTICLES

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Pricing of drugs – at what cost?

Article | February 27, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

5 Pharma Trends and Their Impact on Packaging

Article | February 27, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Spotlight

STADA

STADA Arzneimittel AG as parent company of the STADA Group based in Bad Vilbel, Germany, is a publicly-listed, internationally oriented company.

Events